Article
The drug that pleases by paralysis is no reason to party, even in the wake of FDA approval.
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Arcutis Submits sNDA for Roflumilast Cream 0.3% to Treat Plaque Psoriasis in Patients as Young as 2
The Cutaneous Connection: Combatting Treatment Skepticism in Advanced Pediatric Atopic Dermatitis
Examining Bond-Building Hair Care Treatments
The Cutaneous Connection: Using the Color Wheel to Discuss Nutrition
Recognizing and Managing Pediatric Summer Skin Eruptions
Science of Skin Summit to Spotlight Breakthrough Products and Disruptive Innovations in Dermatology
How the COVID-19 Pandemic Disrupted Melanoma Diagnosis and Treatment
Equity in Melanoma Survival Masks Inequity in Diagnosis
HS TRUTHS Spotlights Hidden Patient Realities